WeVote
Log In

Bill

Bill

H 1581

An Act specifying an electronic system to ensure that sales of certain products containing pseudoephedrine (PSE) do not exceed limits established under federal law

194th Legislature (2025-2026) Introduced by Shirley Arriaga

Massachusetts would establish an electronic system to track pseudoephedrine sales across retailers, preventing purchases exceeding federal limits to combat illegal methamphetamine production.

Accompanied a study order, see H5281 (under House Rule 27)
0
WeVote Research Nonpartisan
Bill Summary · H 1581

Legislative bill overview

H 1581 would require Massachusetts to implement an electronic tracking system to monitor and enforce federal limits on pseudoephedrine (PSE) sales. Pseudoephedrine is a decongestant commonly found in over-the-counter cold medications that can be diverted for illegal methamphetamine production. The bill aims to prevent individuals from purchasing excessive quantities across multiple retailers by creating a statewide electronic database.

Why is this important

Pseudoephedrine is a controlled chemical precursor for methamphetamine manufacturing, and unregulated purchases enable illegal drug production. An electronic system would coordinate sales data across retailers to identify and block bulk purchases that exceed federal limits (currently 3.6 grams per day and 9 grams per 30 days). This addresses a documented gap in enforcement where buyers circumvent limits by visiting multiple stores.

Potential points of contention

  • Privacy concerns: Creating a statewide database tracking over-the-counter medication purchases raises questions about personal health data collection and government surveillance of legal transactions
  • Retailer burden: Pharmacies and stores would face costs and operational complexity to integrate with a new electronic system, potentially passing expenses to consumers
  • Effectiveness debate: Critics argue that determined manufacturers already source pseudoephedrine illegally or use alternative synthesis methods, questioning whether the system justifies its implementation cost
  • Federal adequacy: Some may argue existing federal purchasing limits and DEA oversight are sufficient without state-level duplication

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.